Special items: Ovarian Cancer and Us blog best viewed in Firefox

Saturday, June 25, 2011

Safety Concerns Prompt New Recommendations for Anemia Drugs « news@JAMA (patients with chronic kidney disease)

"The revised recommendations apply to epoetin alfa, which is marketed as Epogen and Procrit, and to darbepoetin alfa, marketed as Aranesp."

No comments:

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.